A Study of Prexasertib (LY2606368), CHK1 Inhibitor, and LY3300054, PD-L1 Inhibitor, in Patients With Advanced Solid Tumors

Summary

This research study is studying a combination of a targeted therapy and an immune therapy as a possible treatment. The drugs involved in this study are: * Prexasertib (LY2606368) * LY3300054

Timeline

Start

2018-05-16

Primary completion

2021-02-01

Completion

2021-02-01

Publications

• Do KT, Manuszak C, Thrash E, Giobbie-Hurder A, Hu J, Kelland S, Powers A, de Jonge A, Shapiro GI, Severgnini M. Immune modulating activity of the CHK1 inhibitor prexasertib and anti-PD-L1 antibody LY3300054 in patients with high-grade serous ovarian cancer and other solid tumors. Cancer Immunol Immunother. 2021 Oct;70(10):2991-3000. doi: 10.1007/s00262-021-02910-x. Epub 2021 Mar 20.

Drugs

Indications